Report of Foreign Issuer (6-k)
08 Septiembre 2020 - 6:45AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of September 2020
Commission
File Number: 001-37643
KITOV
PHARMA LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower, Tel Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On
September 8, 2020, Kitov Pharma Ltd. (the “Company” or the “Registrant”) issued a press release, “Kitov
Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients”, which is attached
hereto as Exhibit 99.1.
Exhibits
Incorporation
by Reference
This Form 6-K,
including all exhibits attached hereto, is hereby incorporated by reference into each
of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12,
2016 (Registration file numbers 333-207117
and 333-211477),
the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration
file number 333-211478), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration
file number 333-218538), the Registrant’s Registration Statement on Form
F-3, as amended, originally filed with the Securities and Exchange Commission on July
16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration
file number 333-230584), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration
file number 333-233795), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration
file number 333-235327), the Registrant’s Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration
file number 333- 238229), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration
file number 333-238481) and each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange
Commission on July 10, 2020 (Registration file numbers 333-239807
and 333-233793),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports
subsequently filed or furnished.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
September 8, 2020
|
KITOV
PHARMA LTD.
|
|
|
|
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac Israel
|
|
|
Chief Executive
Officer
|
2
Kitov Pharma (NASDAQ:KTOV)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024